The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design.
Michael L. Maitland
Consultant or Advisory Role - Astellas Pharma
Sai-Hong Ignatius Ou
No relevant relationships to disclose
Anthony W. Tolcher
Consultant or Advisory Role - Astellas Pharma
Patricia LoRusso
Consultant or Advisory Role - Astellas Pharma
Erkut Bahceci
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Astellas Pharma
Howard A Ball
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Astellas Pharma
Jung Wook Park
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Astellas Pharma
Geoff Yuen
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Astellas Pharma
Luana Pesco Koplowitz
Employment or Leadership Position - Duck Flats Pharma
Consultant or Advisory Role - Astellas Pharma
Tianhong Li
Consultant or Advisory Role - Astellas Pharma